Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 10/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 8/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.49 |
| ▸ | MBTD1 | Q05BQ5 | 4/20 | 0.48 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.48 |
| ▸ | L3MBTL4 | Q8NA19 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1169593 | 0.99 | L3MBTL3 (0.52) | L3MBTL3L3MBTL1HRH3MBTD1TP53BP1 | |
| SCHEMBL600062 | 0.91 | L3MBTL3 (0.44) | L3MBTL3L3MBTL1HRH3MBTD1KDM4E | |
| SCHEMBL1170059 | 0.84 | L3MBTL3 (0.54) | L3MBTL3L3MBTL1HRH3MBTD1TP53BP1 | |
| SCHEMBL1169333 | 0.82 | L3MBTL3 (0.54) | L3MBTL3L3MBTL1HRH3MBTD1TP53BP1 | |
| SCHEMBL4668242 | 0.81 | HRH3 (0.41) | HRH3GPR119 | |
| SCHEMBL4666773 | 0.81 | HRH3 (0.41) | HRH3GPR119 | |
| SCHEMBL4666695 | 0.81 | HRH3 (0.41) | HRH3GPR119 | |
| SCHEMBL1169899 | 0.81 | CHRNA7 (0.55) | HRH3GPR119 | |
| Hydrochloric Acid SCHEMBL4666655 | 0.80 | HRH3 (0.40) | HRH3GPR119 | |
| Hydrochloric Acid SCHEMBL4668308 | 0.80 | HRH3 (0.40) | HRH3GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8492375-B2 | 1-benzoyl substituted diazepine derivatives as selective histamine H3 receptor agonists | GLAXO GROUP LIMITED (GB) | 2013-07-23 | — | — | US | claimed |
| US-20110039833-A1 | 1-BENZOYL SUBSTITUTED DIAZEPINE DERIVATIVES AS SELECTIVE HISTAMINE H3 RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2011-02-17 | — | — | US | claimed |
| US-20080045505-A1 | 1-Benzoyl Substituted Diazepine Derivatives As Selective Histamine H3 Receptor Agonists | GLAXO GROUP LIMITED (GB) | 2008-02-21 | — | — | US | claimed |
| US-8492375-B2 | 1-benzoyl substituted diazepine derivatives as selective histamine H3 receptor agonists | GLAXO GROUP LIMITED (GB) | 2013-07-23 | — | — | US | disclosed |
| US-8492375-B2 | 1-benzoyl substituted diazepine derivatives as selective histamine H3 receptor agonists | GLAXO GROUP LIMITED (GB) | 2013-07-23 | — | — | US | disclosed |
| US-20110039833-A1 | 1-BENZOYL SUBSTITUTED DIAZEPINE DERIVATIVES AS SELECTIVE HISTAMINE H3 RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2011-02-17 | — | — | US | disclosed |
| US-20110039833-A1 | 1-BENZOYL SUBSTITUTED DIAZEPINE DERIVATIVES AS SELECTIVE HISTAMINE H3 RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2011-02-17 | — | — | US | disclosed |
| US-7846922-B2 | 1-benzoyl substituted diazepine derivatives as selective histamine H3 receptor agonists | GLAXO GROUP LIMITED (GB) | 2010-12-07 | — | — | US | disclosed |
| US-7846922-B2 | 1-benzoyl substituted diazepine derivatives as selective histamine H3 receptor agonists | GLAXO GROUP LIMITED (GB) | 2010-12-07 | — | — | US | disclosed |
| US-20080045505-A1 | 1-Benzoyl Substituted Diazepine Derivatives As Selective Histamine H3 Receptor Agonists | GLAXO GROUP LIMITED (GB) | 2008-02-21 | — | — | US | disclosed |
| US-20080045505-A1 | 1-Benzoyl Substituted Diazepine Derivatives As Selective Histamine H3 Receptor Agonists | GLAXO GROUP LIMITED (GB) | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039833-A1 | 1-BENZOYL SUBSTITUTED DIAZEPINE DERIVATIVES AS SELECTIVE HISTAMINE H3 RECEPTOR AGONISTS | HRH3, HRH4, HRH1 | L3MBTL3 3902/4885L3MBTL1 3558/4885HRH3 1/4885 |
| US-20080045505-A1 | 1-Benzoyl Substituted Diazepine Derivatives As Selective Histamine H3 Receptor Agonists | HRH3, HRH4, HRH1 | L3MBTL3 4686/4885L3MBTL1 4312/4885HRH3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.